FDMT – 4d molecular therapeutics, inc. (US:NASDAQ)

News

4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
4DMT Provides Company Update and Anticipated Development Milestones for 2026
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely [Yahoo! Finance]
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop [Seeking Alpha]
4D Molecular Therapeutics (NASDAQ:FDMT) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $26.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com